In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Crucell plans to acquire Swiss vaccines company Berna Biotech

Executive Summary

Dutch biotech Crucell NV (antibodies/vaccines for infectious diseases) has bid to acquire public Swiss vaccines and antibody company Berna Biotech AG. The combined company, retaining the Crucell name, would be headquartered in the Netherlands and will list on the Euronext, Nasdaq, and SWX exchanges.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies